8-K: Current report filing
Published on
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. DATE OF
REPORT (Date of earliest event reported) November 30, 1998.
SONUS PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
DELAWARE 0-26866 95-4343413
(State of Other (Commission (IRS Employer Identification
Jurisdiction of File Number) Number)
Incorporation)
22026 20TH AVE. SE, BOTHELL, WASHINGTON 98021
(Address of Principal Executive Offices)
(425) 487-9500
(Registrant's Telephone Number, Including Area Code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Page 1 of 6
Exhibit Index on Page 4
ITEMS 1 THROUGH 4 AND 6 THROUGH 9 NOT APPLICABLE.
ITEM 5 OTHER EVENTS.
Reference is made to the press release issued to the public by the registrant on
November 30, 1998 relating to the termination of the Agreement with Daiichi
Pharmaceuticals Co., Ltd., the text of which is attached hereto as Exhibit 99.3
for a description of the events reported pursuant to this Form 8-K.
Page 2 of 6
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
SONUS PHARMACEUTICALS, INC.
Date: December 4, 1998 By: /s/ Gregory Sessler
--------------------
Gregory Sessler
Chief Financial Officer and Assistant
Secretary (Principal Financial and
Accounting Officer)
Page 3 of 6
EXHIBIT INDEX
<TABLE>
<CAPTION>
SEQUENTIAL
EXHIBIT NO. DESCRIPTION PAGE. NO.
- ---------- ----------- ----------
<S> <C> <C>
99.3 Press Release date November 30, 1998. 5
</TABLE>
Page 4 of 6